Node1	Edge_Type	Node2	Weight	Score	Paper_List	Original_Text
oxytocin	mechanism_to_anatomy	, 2	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	mechanism_to_anatomy	2	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	mechanism_to_anatomy	facial expression	3	0	31096266|31096266|33622389	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:31096266; Original text:Quantitative facial expression analyses successfully verified the positive effects of repeated oxytocin on autistic individuals' facial expressions and demonstrated a time-course change in efficacy.|PMID:33622389; Original text:The increase in N,N-dimethylglycine was significantly correlated with oxytocin-induced clinical changes, assessed as changes in quantifiable characteristics of autistic facial expression, including both of improvements between baseline and 2 weeks (Pfalse discovery rate = 0.006, r = - 0.485, N = 43) and deteriorations between 2 and 4 weeks
oxytocin	mechanism_to_anatomy	4	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	mechanism_to_anatomy	, and	2	0	31096266|28467893	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:28467893; Original text:A single dose of intranasal oxytocin significantly improved the recognition of basic emotions, particularly fear, and increased the expression of positive emotions among the healthy individuals.
oxytocin	mechanism_to_anatomy	(p	7	0	31096266|34062986|24352377|24352377|26336909|31229634|25149412	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:34062986; Original text:We observed improvements in Aberrant Behavior Checklist and the Social Responsiveness Scale scores and significant improvements in the Clinical Global Impression-improvement between those receiving probiotics and oxytocin combination therapy compared to those receiving placebo (p < 0.05).|PMID:24352377; Original text:Intranasal oxytocin enabled the participants to make the nonverbal information-based judgments more frequently (P = .03) with shorter response time (P = .02).|PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Data obtained from 18 participants who completed the trial showed that 6-week intranasal administration of oxytocin significantly reduced autism core symptoms specific to social reciprocity, which was clinically evaluated by Autism Diagnostic Observation Scale (P = 0.034, PFDR < 0.05, Cohen's d = 0.78).|PMID:31229634; Original text:Results revealed a marginal significant interaction effect between treatment, condition and task (p = 0.054), with Bonferroni-corrected post-hoc tests indicating that The neuropeptide oxytocin specifically increased antisaccade errors for social stimuli (ps < 0.04, effect sizes 0.46-0.88), but not non-social stimuli.|PMID:25149412; Original text:Behaviourally, oxytocin significantly increased the correct rate in inferring others' social emotions (P = 0.043, one-tail).
oxytocin	mechanism_to_anatomy	6	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
brain	mechanism_to_anatomy	levels of	1	0	27654278	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).
brain	mechanism_to_anatomy	of all	1	0	27654278	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).
brain	mechanism_to_anatomy	peripheral blood	1	0	27654278	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).
brain	mechanism_to_anatomy	of brain	1	0	27654278	PMID:27654278; Original text:Random-effects meta-analysis of all 19 studies showed that children with disorder had significantly increased peripheral blood levels of brain-derived neurotrophic factor compared with healthy controls (Hedges g, 0.490; 95% CI, 0.185-0.794; P = .002).
brain-derived neurotrophic factor	mechanism_to_anatomy	levels of	2	0	27654278|33420109	PMID:27654278; Original text:Subgroup analyses in 4 studies revealed that neonates diagnosed with disorder later in life had no association with blood levels of brain-derived neurotrophic factor (Hedges g, 0.384; 95% CI, -0.244 to 1.011; P = .23), whereas children in the nonneonate disorder group (15 studies) demonstrated significantly increased brain-derived neurotrophic factor levels compared with healthy controls (Hedges g, 0.524; 95% CI, 0.206 to 0.842; P = .001).|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism_to_anatomy	group (	1	0	27654278	PMID:27654278; Original text:Subgroup analyses in 4 studies revealed that neonates diagnosed with disorder later in life had no association with blood levels of brain-derived neurotrophic factor (Hedges g, 0.384; 95% CI, -0.244 to 1.011; P = .23), whereas children in the nonneonate disorder group (15 studies) demonstrated significantly increased brain-derived neurotrophic factor levels compared with healthy controls (Hedges g, 0.524; 95% CI, 0.206 to 0.842; P = .001).
brain-derived neurotrophic factor	mechanism_to_anatomy	of brain	2	0	27654278|33420109	PMID:27654278; Original text:Subgroup analyses in 4 studies revealed that neonates diagnosed with disorder later in life had no association with blood levels of brain-derived neurotrophic factor (Hedges g, 0.384; 95% CI, -0.244 to 1.011; P = .23), whereas children in the nonneonate disorder group (15 studies) demonstrated significantly increased brain-derived neurotrophic factor levels compared with healthy controls (Hedges g, 0.524; 95% CI, 0.206 to 0.842; P = .001).|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
tcf4 gene	mechanism_to_anatomy	nervous system	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene	mechanism_to_anatomy	of the	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene	mechanism_to_anatomy	gene product	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene	mechanism_to_anatomy	central nervous	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene	mechanism_to_anatomy	central nervous system	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene product	mechanism_to_anatomy	nervous system	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene product	mechanism_to_anatomy	of the	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene product	mechanism_to_anatomy	gene product	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene product	mechanism_to_anatomy	central nervous	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
tcf4 gene product	mechanism_to_anatomy	central nervous system	1	0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
gluten	mechanism_to_anatomy	of the	1	0	26418822	PMID:26418822; Original text:When asked about the effects of the gluten-free and casein-free diet, 20-29% of the parents reported significant improvements on the autism spectrum disorder core dimensions.
casein	mechanism_to_anatomy	of the	1	0	26418822	PMID:26418822; Original text:When asked about the effects of the gluten-free and casein-free diet, 20-29% of the parents reported significant improvements on the autism spectrum disorder core dimensions.
httlpr alleles	mechanism_to_anatomy	, a	1	0	16103890	PMID:16103890; Original text:With respect to this locus, there are now seven of 12 studies reporting significant transmission bias of HTTLPR alleles, a noteworthy result in itself.
tumor necrosis factor-α	mechanism_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor necrosis factor-α	mechanism_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interleukin-6	mechanism_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
interferon-γ	mechanism_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
il-6	mechanism_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
ifn-γ	mechanism_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	blood	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	, brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	cerebrospinal fluid	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	, and	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	, a	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	brain	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tnf-α	mechanism_to_anatomy	, tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
kiaa0319l	mechanism_to_anatomy	tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
kiaa0319l	mechanism_to_anatomy	, tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
tdo2	mechanism_to_anatomy	tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
tdo2	mechanism_to_anatomy	, tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
chd1l	mechanism_to_anatomy	tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
chd1l	mechanism_to_anatomy	, tissue	1	0	31685286	PMID:31685286; Original text:For brain tissue, Tissue specific transcriptome-wide association study identified 148 genes with P value < 0.05, such as TDO2 (PTissue specific transcriptome-wide association study=4.01×10-2), CHD1L (PTissue specific transcriptome-wide association study=9.64×10-3) and KIAA0319L (PTissue specific transcriptome-wide association study=4.05×10-4).
mtor	mechanism_to_anatomy	, and	1	0	32222129	PMID:32222129; Original text:Animal studies have demonstrated the benefit of using mTOR inhibitors for various symptoms of Tuberous sclerosis complex, and they have been successfully translated into clinical trials with significant improvement in symptom burden.
mtor	mechanism_to_anatomy	complex	1	0	32222129	PMID:32222129; Original text:Animal studies have demonstrated the benefit of using mTOR inhibitors for various symptoms of Tuberous sclerosis complex, and they have been successfully translated into clinical trials with significant improvement in symptom burden.
growth hormone	mechanism_to_anatomy	growth hormone	2	0	10808042|10649829	PMID:10808042; Original text:This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects.|PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
oxytocin	mechanism_to_anatomy	, a	1	0	33622389	PMID:33622389; Original text:Among the 35 metabolites measured, a significant increase in N,N-dimethylglycine was detected in the subjects administered oxytocin compared with those given placebo at a medium effect size (false discovery rate (false discovery rate) corrected P = 0.043, d = 0.74, N = 83).
oxytocin	mechanism_to_anatomy	of the	5	0	33622389|27071789|32161366|27651096|8759044	"PMID:33622389; Original text:Furthermore, subgroup analyses of the participants displaying a prominent time-course change in oxytocin efficacy revealed a significant effect of oxytocin on N,N-dimethylglycine levels with a large effect size (Pfalse discovery rate = 0.004, d = 1.13, N = 60).|PMID:27071789; Original text:Some studies have reported significant improvement of the core symptoms of disorder by long-term oxytocin administration, while other studies showed no such improvement.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:27651096; Original text:Despite these limitations in the field to date, there remains significant potential for oxytocin to ameliorate aspects of the persistent and debilitating social impairments in individuals with disorder.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	mechanism_to_anatomy	and 2	1	0	33622389	PMID:33622389; Original text:The increase in N,N-dimethylglycine was significantly correlated with oxytocin-induced clinical changes, assessed as changes in quantifiable characteristics of autistic facial expression, including both of improvements between baseline and 2 weeks (Pfalse discovery rate = 0.006, r = - 0.485, N = 43) and deteriorations between 2 and 4 weeks
casein	mechanism_to_anatomy	gastrointestinal system	1	0	33573238	PMID:33573238; Original text:There has been a growing interest in the gastrointestinal system and its significance for autism spectrum disorder (spectrum disorder), including the significance of adopting a gluten-free and casein-free (GFCF) diet.
neurotensin	mechanism_to_anatomy	mitochondrial	2	0	23570274|23688533	PMID:23570274; Original text:neurotensin is significantly increased in serum of ASD children along with mitochondrial DNA (mitochondrial DNA).|PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
secretin	mechanism_to_anatomy	of the	5	0	11699803|15590241|15590241|10588965|15937041	PMID:11699803; Original text:For the primary efficacy analysis, change of the Autism Diagnostic Observation Schedule social-communication total score from week 0 to week 4, no statistically significant difference was obtained between placebo (-0.8 +/- 2.9) and secretin groups (-0.6 +/- 1.4; t54 = 0.346, p < .73).|PMID:15590241; Original text:Journal of the Association of the Academy of Minority Physicians, 9, 9-15] reported an uncontrolled trial of secretin with three participants with autism, which apparently resulted in significant behavioral improvement.|PMID:15590241; Original text:Almost none of the studies reported any significant effects and none concluded that secretin was effective.|PMID:10588965; Original text:As compared with placebo, secretin treatment was not associated with significant improvements in any of the outcome measures.|PMID:15937041; Original text:Improvement in speech was found during the treatment phase of the trial (p=0.0479 for secretin versus placebo) only in children not using other medications.
secretin	mechanism_to_anatomy	4	1	0	11699803	PMID:11699803; Original text:For the primary efficacy analysis, change of the Autism Diagnostic Observation Schedule social-communication total score from week 0 to week 4, no statistically significant difference was obtained between placebo (-0.8 +/- 2.9) and secretin groups (-0.6 +/- 1.4; t54 = 0.346, p < .73).
foxp3	mechanism_to_anatomy	b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	memory b	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	, memory	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	memory b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	lymphocyte	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	, and	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
foxp3	mechanism_to_anatomy	cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	memory b	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	, memory	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	memory b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	lymphocyte	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	, and	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
toll-like receptor-4	mechanism_to_anatomy	cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	memory b	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	, memory	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	memory b cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	lymphocyte	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	, and	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
cd40 ligand	mechanism_to_anatomy	cells	1	0	29427532	PMID:29427532; Original text:Secondary endpoints included experimental biomarkers such as CD40 ligand, toll-like receptor-4, memory B cells, FOXP3, and lymphocyte stimulation.
serotonin transporter	mechanism_to_anatomy	striatum	1	0	28738293	PMID:28738293; Original text:However, the increased serotonin transporter (SERT) level in the striatum after treatment was correlated significantly with increased negative emotional response to human faces.
sert	mechanism_to_anatomy	striatum	1	0	28738293	PMID:28738293; Original text:However, the increased serotonin transporter (SERT) level in the striatum after treatment was correlated significantly with increased negative emotional response to human faces.
oxytocin	mechanism_to_anatomy	prefrontal cortex	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	mechanism_to_anatomy	medial prefrontal	4	0	24352377|26336909|26336909|30262887	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).|PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
oxytocin	mechanism_to_anatomy	medial prefrontal cortex	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	mechanism_to_anatomy	cortex (	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
il-17+domain-3+	mechanism_to_anatomy	, and	1	0	30590210	PMID:30590210; Original text:+, IFN-γ+domain-3+, and IL-17+domain-3+, and decreased Foxp3+domain-3+ production compared with that in TD controls.
foxp3+domain-3+	mechanism_to_anatomy	, and	1	0	30590210	PMID:30590210; Original text:+, IFN-γ+domain-3+, and IL-17+domain-3+, and decreased Foxp3+domain-3+ production compared with that in TD controls.
ifn-γ+domain-3+	mechanism_to_anatomy	, and	1	0	30590210	PMID:30590210; Original text:+, IFN-γ+domain-3+, and IL-17+domain-3+, and decreased Foxp3+domain-3+ production compared with that in TD controls.
mdr1	mechanism_to_anatomy	(p	1	0	20166790	PMID:20166790; Original text:Subjects with either C/T or C/C (n = 16) genotypes showed a three-fold greater improvement than T/T MDR1 C3435T genotype (n = 6) (mean decrease of 15.1 +/- 12.6, or 50.7% from baseline, versus 4.5 +/- 5.1, or 15.6% from baseline) in parent-rated ABC Hyperactivity scores over 8 weeks (p = 0.03).
alpha-amylase	mechanism_to_anatomy	, alpha	1	0	34237553	PMID:34237553; Original text:Data were analyzed with mixed models for outcome measures cortisol, alpha-amylase, heart rate variability and sympathetic activity.
alpha-amylase	mechanism_to_anatomy	, heart	1	0	34237553	PMID:34237553; Original text:Data were analyzed with mixed models for outcome measures cortisol, alpha-amylase, heart rate variability and sympathetic activity.
activator protein 1	mechanism_to_anatomy	protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
activator protein 1	mechanism_to_anatomy	b (	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
nuclear factor kappa b	mechanism_to_anatomy	protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
nuclear factor kappa b	mechanism_to_anatomy	b (	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
ap-1	mechanism_to_anatomy	protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
ap-1	mechanism_to_anatomy	b (	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
nf-κb	mechanism_to_anatomy	protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
nf-κb	mechanism_to_anatomy	b (	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
methionine synthase	mechanism_to_anatomy	levels of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
methionine synthase	mechanism_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
the serotonin transporter gene polymorphisms	mechanism_to_anatomy	of the	1	0	18286633	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
the	mechanism_to_anatomy	of the	1	0	18286633	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
serotonin transporter genelpr	mechanism_to_anatomy	of the	1	0	18286633	PMID:18286633; Original text:However, there was significant heterogeneity by ethnicity; family based studies of US mixed population samples showed preferential transmission of the S allele of The serotonin transporter geneLPR (S allele:
s allele	mechanism_to_anatomy	of the	1	0	18286633	PMID:18286633; Original text:However, there was significant heterogeneity by ethnicity; family based studies of US mixed population samples showed preferential transmission of the S allele of The serotonin transporter geneLPR (S allele:
neurotensin	mechanism_to_anatomy	the brain	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
neurotensin	mechanism_to_anatomy	mast cell	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
neurotensin	mechanism_to_anatomy	secretion of	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
neurotensin	mechanism_to_anatomy	secretion	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
oxytocin	mechanism_to_anatomy	the brain	1	0	25416642	PMID:25416642; Original text:Here we extend our previous work by significantly increasing the number of participants to enable the use of more stringent statistical thresholds that permit more precise localization of oxytocin and vasopressin effects in the brain.
vasopressin	mechanism_to_anatomy	the brain	1	0	25416642	PMID:25416642; Original text:Here we extend our previous work by significantly increasing the number of participants to enable the use of more stringent statistical thresholds that permit more precise localization of oxytocin and vasopressin effects in the brain.
oxytocin receptor gene	mechanism_to_anatomy	, a	1	0	25092245	PMID:25092245; Original text:Thus, a meta-analytic review of extant studies is needed to determine whether The oxytocin receptor gene shows association with disorder, and to elucidate which specific single-nucleotide polymorphisms have a significant effect on disorder.
oxytocin receptor gene	mechanism_to_anatomy	, and	1	0	25092245	PMID:25092245; Original text:Thus, a meta-analytic review of extant studies is needed to determine whether The oxytocin receptor gene shows association with disorder, and to elucidate which specific single-nucleotide polymorphisms have a significant effect on disorder.
blood	mechanism_to_anatomy	of blood	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
blood	mechanism_to_anatomy	blood brain	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
brain	mechanism_to_anatomy	of blood	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
brain	mechanism_to_anatomy	blood brain	1	0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
fra	mechanism_to_anatomy	cerebrospinal fluid	1	0	22230883	PMID:22230883; Original text:In 16 children, the concentration of blocking FRA significantly correlated with cerebrospinal fluid 5-methyltetrahydrofolate concentrations, which were below the normative mean in every case.
beta-endorphin	mechanism_to_anatomy	group (	1	0	2977280	PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.
beta-endorphin	mechanism_to_anatomy	(p	1	0	2977280	PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.
growth factor-β1	mechanism_to_anatomy	levels of	1	0	29298441	PMID:29298441; Original text:Plasma levels of growth factor-β1 significantly increased to 85% immediately after auditory integrative training (20.13 ± 12 ng/mL, p < 0.05), to 95% 1 month after auditory integrative training (21.2 ± 11 ng/mL, p < 0.01), and to 105% 3 months after auditory integrative training (22.25 ± 16 ng/mL, p < 0.01) compared to before auditory integrative training (10.85 ± 8 ng/mL).
growth factor-β1	mechanism_to_anatomy	, and	1	0	29298441	PMID:29298441; Original text:Plasma levels of growth factor-β1 significantly increased to 85% immediately after auditory integrative training (20.13 ± 12 ng/mL, p < 0.05), to 95% 1 month after auditory integrative training (21.2 ± 11 ng/mL, p < 0.01), and to 105% 3 months after auditory integrative training (22.25 ± 16 ng/mL, p < 0.01) compared to before auditory integrative training (10.85 ± 8 ng/mL).
secretin	mechanism_to_anatomy	9	1	0	15590241	PMID:15590241; Original text:Journal of the Association of the Academy of Minority Physicians, 9, 9-15] reported an uncontrolled trial of secretin with three participants with autism, which apparently resulted in significant behavioral improvement.
interleukin-8	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-8	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin)-1beta	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin)-1beta	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
transforming growth factor-β1	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
transforming growth factor-β1	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
monocyte chemotactic protein-1	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
monocyte chemotactic protein-1	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-6	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin-6	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interleukin	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism_to_anatomy	monocyte	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
interferon-gamma	mechanism_to_anatomy	group	1	0	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
oxytocin	mechanism_to_anatomy	anterior cingulate cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	mechanism_to_anatomy	anterior cingulate	2	0	26336909|26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).
oxytocin	mechanism_to_anatomy	cingulate cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	mechanism_to_anatomy	cortex and	2	0	26336909|32161366	"PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
zonulin peptide family	mechanism_to_anatomy	levels of	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
zonulin peptide family	mechanism_to_anatomy	of the	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
zonulin peptide family	mechanism_to_anatomy	(p	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
zonulin	mechanism_to_anatomy	levels of	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
zonulin	mechanism_to_anatomy	of the	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
zonulin	mechanism_to_anatomy	(p	1	0	32635367	PMID:32635367; Original text:A meta-analysis of mean zonulin plasma levels of patients and control groups revealed a significant difference between groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
extracellular signal-related kinase	mechanism_to_anatomy	of peripheral	1	0	21059347	PMID:21059347; Original text:Overall, riluzole use was not associated with significant clinical improvement despite uniform correction of peripheral Extracellular signal-related kinase activation.
2d6	mechanism_to_anatomy	of the	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
2d6	mechanism_to_anatomy	, and	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
5-httlpr gene	mechanism_to_anatomy	of the	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
5-httlpr gene	mechanism_to_anatomy	, and	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
cytochrome p450 2c19	mechanism_to_anatomy	of the	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
cytochrome p450 2c19	mechanism_to_anatomy	, and	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
maoa	mechanism_to_anatomy	of the	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
maoa	mechanism_to_anatomy	, and	1	0	28242040	PMID:28242040; Original text:Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study.
basic fibroblast growth factor	mechanism_to_anatomy	fibroblast	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
basic fibroblast growth factor	mechanism_to_anatomy	vascular endothelial	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
basic fibroblast growth factor	mechanism_to_anatomy	cerebrospinal fluid	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
basic fibroblast growth factor	mechanism_to_anatomy	endothelial	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
basic fibroblast growth factor	mechanism_to_anatomy	transplantation	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
vascular endothelial growth factor	mechanism_to_anatomy	fibroblast	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
vascular endothelial growth factor	mechanism_to_anatomy	vascular endothelial	2	0	26345804|33420109	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism_to_anatomy	cerebrospinal fluid	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
vascular endothelial growth factor	mechanism_to_anatomy	endothelial	2	0	26345804|33420109	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism_to_anatomy	transplantation	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
nerve growth factor	mechanism_to_anatomy	fibroblast	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
nerve growth factor	mechanism_to_anatomy	vascular endothelial	2	0	26345804|33420109	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism_to_anatomy	cerebrospinal fluid	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
nerve growth factor	mechanism_to_anatomy	endothelial	2	0	26345804|33420109	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.|PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism_to_anatomy	transplantation	1	0	26345804	PMID:26345804; Original text:nerve growth factor levels in the the cerebrospinal fluid were significantly increased after transplantation (213.54 ± 56.38 after the third versus 28.32 ± 12.22 ng/L after the first transplantation; P < 0.05), while vascular endothelial growth factor and basic fibroblast growth factor levels did not change significantly.
prolactin	mechanism_to_anatomy	(p	2	0	15142390|17224713	PMID:15142390; Original text:In all children, serum prolactin levels increased significantly (p < 0.001) from 166 +/- 88 UI/mL at baseline to 504 +/- 207 UI/mL at week 12 of risperidone treatment.|PMID:17224713; Original text:SD prolactin levels increased from 7.8 +/- 8.0 ng/mL at baseline to 33.2 +/- 12.8 ng/mL at week 8 (P < 0.001), with a slight decrease to 28.8 +/-
oxytocin	mechanism_to_anatomy	the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	mechanism_to_anatomy	of the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	mechanism_to_anatomy	superior temporal	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	mechanism_to_anatomy	temporal	2	0	32161366|8759044	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	mechanism_to_anatomy	orbitofrontal cortex	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	mechanism_to_anatomy	amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	mechanism_to_anatomy	temporal sulcus	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
folate receptor alpha	mechanism_to_anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha	mechanism_to_anatomy	, a	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha	mechanism_to_anatomy	, and	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha	mechanism_to_anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha	mechanism_to_anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism_to_anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism_to_anatomy	, a	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism_to_anatomy	, and	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism_to_anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	mechanism_to_anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	mechanism_to_anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	mechanism_to_anatomy	, a	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	mechanism_to_anatomy	, and	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	mechanism_to_anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate receptor alpha autoantibodies	mechanism_to_anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
immunoglobulins	mechanism_to_anatomy	levels of	1	0	30577568	PMID:30577568; Original text:Altered levels of cytokines, chemokines and immunoglobulins were demonstrated in patients with disorders; in particular, proinflammatory mediators were significantly increased.
epidermal growth factor	mechanism_to_anatomy	levels of	1	0	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
epidermal growth factor	mechanism_to_anatomy	, and	1	0	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
il-13	mechanism_to_anatomy	levels of	1	0	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
il-13	mechanism_to_anatomy	, and	1	0	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
pten	mechanism_to_anatomy	neural stem	1	0	24136242	PMID:24136242; Original text:Particularly, accumulated data suggest that the effect of PTEN on neural stem-cell development contributes significantly to the pathophysiology of autism spectrum disorders.
il-1β	mechanism_to_anatomy	(p	1	0	32121236	PMID:32121236; Original text:When only children with elevated IL-1β were included, five outcomes showed greater improvements: OM (P = 0.01) for SRS-total; OM (P = 0.03) for SRS-social communicative functioning; VID (P = 0.01), OM (P = 0.003) and VIDOM (P = 0.01) for SRS-awareness.
serotonin	mechanism_to_anatomy	cortex	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	mechanism_to_anatomy	receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	mechanism_to_anatomy	, and	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	mechanism_to_anatomy	terminals	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin receptors	mechanism_to_anatomy	cortex	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin receptors	mechanism_to_anatomy	receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin receptors	mechanism_to_anatomy	, and	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin receptors	mechanism_to_anatomy	terminals	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
slc6a4 5-httlpr polymorphism	mechanism_to_anatomy	, 3	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
slc6a4 5-httlpr polymorphism	mechanism_to_anatomy	3 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
slc6a4 5-httlpr polymorphism	mechanism_to_anatomy	, 2	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
slc6a4 5-httlpr polymorphism	mechanism_to_anatomy	2 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
drd3 ser9gly	mechanism_to_anatomy	, 3	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
drd3 ser9gly	mechanism_to_anatomy	3 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
drd3 ser9gly	mechanism_to_anatomy	, 2	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
drd3 ser9gly	mechanism_to_anatomy	2 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
peripheral c-reactive protein	mechanism_to_anatomy	, peripheral	1	0	32272227	PMID:32272227; Original text:In our study, peripheral C-reactive protein levels were significantly elevated in autistic children compared with healthy children.
hemoglobin	mechanism_to_anatomy	inferior frontal gyrus	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	pars opercularis	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	of the	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	frontal gyrus	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	of the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	the inferior	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
hemoglobin	mechanism_to_anatomy	inferior frontal	1	0	25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.
low-density lipoprotein cholesterol	mechanism_to_anatomy	, and	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
high-density lipoprotein cholesterol	mechanism_to_anatomy	, and	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
monocyte chemoattractant protein-1	mechanism_to_anatomy	of the	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
monocyte chemoattractant protein-1	mechanism_to_anatomy	monocyte	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
monocyte chemoattractant protein-1	mechanism_to_anatomy	, 2	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
monocyte chemoattractant protein-1	mechanism_to_anatomy	2 of	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
eotaxin	mechanism_to_anatomy	of the	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
eotaxin	mechanism_to_anatomy	monocyte	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
eotaxin	mechanism_to_anatomy	, 2	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
eotaxin	mechanism_to_anatomy	2 of	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
oxytocin	mechanism_to_anatomy	of primary	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	mechanism_to_anatomy	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	mechanism_to_anatomy	of temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	mechanism_to_anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
foxg1	mechanism_to_anatomy	, a	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
foxg1	mechanism_to_anatomy	of the	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
foxg1	mechanism_to_anatomy	(p	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
foxg1	mechanism_to_anatomy	, and	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
cntnap2 gene	mechanism_to_anatomy	, and	1	0	26559825	PMID:26559825; Original text:Overall, including case-control, sibs, and meta-analysis, we could not detect any significant association with the CNTNAP2 gene and high functioning ASD.
dgcr6 genes	mechanism_to_anatomy	(p	1	0	19736351	PMID:19736351; Original text:Individual significance (P = .02 without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.
prodh	mechanism_to_anatomy	(p	1	0	19736351	PMID:19736351; Original text:Individual significance (P = .02 without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.
spon1 variant	mechanism_to_anatomy	chromosome 11	1	0	23471985	PMID:23471985; Original text:The association of connectivity with the SPON1 variant at rs2618516 on chromosome 11 (11p15.2) reached connectome-wide, genome-wide significance after stringent statistical corrections were enforced, and it was replicated in an independent subsample.
spon1 variant	mechanism_to_anatomy	, and	1	0	23471985	PMID:23471985; Original text:The association of connectivity with the SPON1 variant at rs2618516 on chromosome 11 (11p15.2) reached connectome-wide, genome-wide significance after stringent statistical corrections were enforced, and it was replicated in an independent subsample.
spon1 variant	mechanism_to_anatomy	chromosome	1	0	23471985	PMID:23471985; Original text:The association of connectivity with the SPON1 variant at rs2618516 on chromosome 11 (11p15.2) reached connectome-wide, genome-wide significance after stringent statistical corrections were enforced, and it was replicated in an independent subsample.
blood	mechanism_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism_to_anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism_to_anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism_to_anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood	mechanism_to_anatomy	endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism_to_anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism_to_anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vascular endothelial growth factor	mechanism_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vegf	mechanism_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vegf	mechanism_to_anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vegf	mechanism_to_anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vegf	mechanism_to_anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vegf	mechanism_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
vegf	mechanism_to_anatomy	endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism_to_anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism_to_anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism_to_anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
blood neurotrophin-3	mechanism_to_anatomy	endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism_to_anatomy	vascular endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
brain-derived neurotrophic factor	mechanism_to_anatomy	endothelial	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism_to_anatomy	peripheral blood	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism_to_anatomy	of brain	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism_to_anatomy	levels of	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
nerve growth factor	mechanism_to_anatomy	, nerve	1	0	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
leptin	mechanism_to_anatomy	, and	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
leptin	mechanism_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
leptin	mechanism_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	mechanism_to_anatomy	, and	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	mechanism_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	mechanism_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine aminotransferase	mechanism_to_anatomy	, and	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine aminotransferase	mechanism_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine aminotransferase	mechanism_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
hemoglobin a1c	mechanism_to_anatomy	, and	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
hemoglobin a1c	mechanism_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
hemoglobin a1c	mechanism_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
en2 gene	mechanism_to_anatomy	(p	1	0	22522212	PMID:22522212; Original text:Furthermore, we detected an interaction effect on age of first phrase between a SNP rs2228946 in the WNT2 gene and another SNP rs6460013 in the EN2 gene (p = 0.0012).
wnt2 gene	mechanism_to_anatomy	(p	1	0	22522212	PMID:22522212; Original text:Furthermore, we detected an interaction effect on age of first phrase between a SNP rs2228946 in the WNT2 gene and another SNP rs6460013 in the EN2 gene (p = 0.0012).
